作者:Mikko Gynther、Krista Laine、Jarmo Ropponen、Jukka Leppänen、Anne Mannila、Tapio Nevalainen、Jouko Savolainen、Tomi Järvinen、Jarkko Rautio
DOI:10.1021/jm701175d
日期:2008.2.1
of drug molecules into the brain. We describe a feasible means to achieve carrier-mediated drug transport into the rat brain via the specific, large neutral amino acid transporter (LAT1) by conjugating a model compound to L-tyrosine. A hydrophilic drug, ketoprofen, that is not a substrate for LAT1 was chosen as a model compound. The mechanism and the kinetics of the brain uptake of the prodrug were
血脑屏障有效地控制了药物分子进入大脑。我们描述了一种可行的方法,可通过将模型化合物与L-酪氨酸缀合,通过特定的大型中性氨基酸转运蛋白(LAT1)实现载体介导的药物转运到大鼠脑内。选择不是LAT1底物的亲水性药物酮洛芬作为模型化合物。用原位大鼠脑灌注技术确定前药对大脑的吸收机理和动力学。发现前药的脑摄取是浓度依赖性的。此外,特定的LAT1抑制剂可显着降低前药对大脑的吸收。因此,我们的结果首次揭示了药物-底物偶联物能够通过LAT1将药物转运到大脑中。